Amryt Pharma PLC (LON:FAST)‘s stock had its “speculative buy” rating reiterated by investment analysts at Beaufort Securities in a report issued on Tuesday. They presently have a GBX 65 ($0.85) price target on the stock. Beaufort Securities’ price target points to a potential upside of 268.69% from the company’s current price.
Amryt Pharma PLC (FAST) opened at GBX 17.63 ($0.23) on Tuesday. Amryt Pharma PLC has a one year low of GBX 13.44 ($0.18) and a one year high of GBX 29.50 ($0.39).
ILLEGAL ACTIVITY NOTICE: “Amryt Pharma PLC (FAST) Earns “Speculative Buy” Rating from Beaufort Securities” was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/amryt-pharma-plc-fast-earns-speculative-buy-rating-from-beaufort-securities.html.
About Amryt Pharma PLC
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102.
Receive News & Ratings for Amryt Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amryt Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.